

# Referenser

## Cannabis: Harmlös rekreation eller farlig drog?

1. Di Forti M, Quattrone D, Freeman TP, Triploi G. et al., The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *Lancet Psychiatry*. E-pub 19 mars 2019.
2. Englund A, Freeman TP, Murray RM & McGuire P. Can we make cannabis safer? *Lancet Psychiatry*. 2017; 4: 643–648.
3. Graddy R, Buresh ME, Rastegar DA. New and Emerging Illicit Psychoactive Substances. *Med Clin North Am*. 2018; 102: 697–714.
4. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. *Clin Toxicol (Phila)*. 2016; 54: 1–13.
5. Kraemer M, Boehmer A, Madea B, Maas A. Death cases involving certain new psychoactive substances: A review of the literature. *Forensic Sci Int*. 2019; 298: 186–267.
6. Centralförbundet för alkohol- och narkotikaupplysning (CAN). Skolelevers drogvänor 2018. Rapport 178. Stockholm 2018.
7. World drug report 2018. Executive summary, conclusions and policy implications. United Nations publication, sales no. E.18.XI.9. Tillgänglig: [https://www.unodc.org/wdr2018/prelaunch/WDR18\\_Booklet\\_1\\_EXSUM.pdf](https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_1_EXSUM.pdf)
8. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) European Drug Report 2018: Trends and Developments Tillgänglig: [http://www.emcdda.europa.eu/system/files/publications/8585/20181816\\_TDAT18001SVN\\_PDF.pdf](http://www.emcdda.europa.eu/system/files/publications/8585/20181816_TDAT18001SVN_PDF.pdf)
9. Folkhälsomyndigheten. Den svenska narkotikasituationen. En översikt. Solna: Folkhälsomyndigheten; 2018. Tillgänglig: <https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/d/den-svenska-narkotikasituationen-en-oversikt/>
10. Centralförbundet för alkohol- och narkotikaupplysning (CAN). Negativa konsekvenser av alkohol, narkotika och tobak. Rapport 174. Stockholm 2018.
11. Gripe I, Danielsson AK, Ramstedt M. Are changes in drinking related to changes in cannabis use among Swedish adolescents? A time-series analysis for the period 1989–2016. *Addiction*. 2018; 113: 1643–1650.
12. World Health Organization. The health and social effects of nonmedical cannabis use. WHO, Geneva 2016. Tillgänglig: [https://www.who.int/substance\\_abuse/publications/msbcannabis.pdf](https://www.who.int/substance_abuse/publications/msbcannabis.pdf)
13. National Academy of Sciences, Engineering and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington DC. The National Academies Press, 2017. Tillgänglig: <https://www.nap.edu/read/24625/chapter/1#ii>
14. Falkstedt D, Wolff V, Allebeck P, Hemmingsson T, Danielsson AK. Cannabis, tobacco, alcohol use and the risk of early stroke: A population based cohort study. *Stroke* 2017; 48: 265–70.
15. Callaghan R, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40 year cohort study. *Cancer Causes Control*. 2013; 24: 1811–1820.
16. Callaghan RC, Allebeck P, Acre O, McGlynn KA, Sidorchuk A. Cannabis use and incidence of testicular cancer: a 42 year follow-up of Swedish men. *Cancer Epidemiol Biomarker Prev* 2017; 26: 1644–52.
17. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. *Nature review* 2007; 8: 885–895.
18. Nordegren T, Tunving K. Hasch – romantik och fakta. Prisma, Stockholm, 1984.
19. Thomas H. Psychiatric symptoms in cannabis users. *British J Psychiatry* 1993; 163: 141–49.
20. Keeler MH, Reifler CB, Liptzin MB. Spontaneous recurrence of marijuana effects *Am J Psychiatry* 1968; 125: 384–86.
21. Meier MH, Caspi A, Ambler A et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Nat Acad Sci* 2012; 109: 2657–64.

22. Rogeberg O. Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding for socioeconomic status, *Proc Nat Acad Sci* 2013; 110: 4251–54.
23. Auer R, Vittinghoff E, Yaffe K, et al. Association between lifetime marijuana use and cognitive function in middle age. *JAMA Intern Med* 2016; 176: 352–61. 24. Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. *Lancet* 1987; 2: 1483–86.
25. Moore THM, Zammit S, Kubfird-Hughes A. et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet*. 2007; 28; 319–28.
26. Ksir C, Hart CL. Cannabis and psychosis: A critical review of the relationship. *Current Psychiatry Reports* 2016; 18: 12.
27. Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. *World Psychiatry* 2016; 15: 195–204.
28. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Allebeck P. Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts. *BMC Psychiatry* 2012; 16; 12: 112
29. Danielsson AK, Lundin A, Agardh E, Allebeck P, Forsell Y. Cannabis use, depression and anxiety: A 3-year prospective population-based study. *J Affect Disord*. 2016; 15; 103–8.
30. Danielsson AK, Lundin A, Allebeck P, Agardh E. Cannabis use and psychological distress: An 8-year prospective population-based study among Swedish men and women. *Addict Behav*. 2016; 59: 18–23
31. Hall, W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? *Addiction*, 2015; 110: 19–35.
32. Nordic Welfare Centre (Stenius K.) Treatment of cannabis-related problems in the Nordic countries. February 2019. Tillgänglig: [https://nordicwelfare.org/wp-content/uploads/2019/02/NWC\\_Cannabis\\_Treatment\\_2019\\_Webb\\_FINAL.pdf](https://nordicwelfare.org/wp-content/uploads/2019/02/NWC_Cannabis_Treatment_2019_Webb_FINAL.pdf)
33. Degenhardt L, Coffey C, Carlin JB et al. Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. *BJP* 2010; 196: 290–295.
34. Legley, S, Obradovic I, Janssen E et al. The mediation role of licit drugs in the influence of socializing on cannabis use among adolescents: A quantitative approach. *European J Publ Health* 2010; 20: 157–163.
35. Fergusson DM & Boden JM. Cannabis use and later life outcomes. *Addiction*, 2008; 103, 969–976.
36. Danielsson AK, Falkstedt D, Hemmingsson T, Allebeck P, Agardh E. Cannabis use among Swedish men in adolescence and the risk of adverse life course outcomes: results from a 20 year-follow-up study. *Addiction*. 2015; 110: 1794–802.
37. Danielsson AK, Agardh E, Hemmingsson T, Allebeck P & Falkstedt D. Cannabis use in adolescence and risk of future disability pension: a 39-year longitudinal cohort study. *Drug and Alcohol Dependence* 2014; 143: 239–243.
38. Pedersen W. Cannabis and social welfare assistance: a longitudinal study. *Addiction* 2011; 106, 1636–1643.
39. Hyggen C. Does smoking cannabis affect work commitment? *Addiction* 2012; 107: 1309–1315.
40. Davstad I, Leifman A, Allebeck P & Romelsjö A. Predictors of a favourable socio-economic situation in middle age for Swedish conscripts with self-reported drug use. *Drug and Alcohol Dependence* 2013; 128, 37– 44.
41. Brook, JS, Lee JY, Finch SJ, Koppel J & Brook DW. Psychosocial Factors Related to Cannabis Use Disorders. *Substance Abuse* 2011; 32: 242–251.
42. Verweij JH, Huizinka AC, Agrawal A, Martin NG & Lynskey MT. Is the relationship between early-onset cannabis use and educational attainment causal or due to common liability? *Drug and Alcohol Dependence* 2013; 133: 580– 586.
43. Bergen SE, Gardner CO, Aggen SH, Kendler KS. Socioeconomic Status and Social Support Following Illicit Drug Use: Causal Pathways or Common Liability? *Twin Res Hum Genet*. 2008; 1: 266–274.
44. Daniel JZ, Hickman M, Macleod J et al. Is socioeconomic status in early life associated with drug use? A systematic review of the evidence *Drug Alc Rev* 2009; 28: 142–153.
45. Charitonidi, E., et al., Socioeconomic status and substance use among Swiss young men: a population-based cross-sectional study. *Bmc Public Health*, 2016; 16: 333.
46. Legleye, S., et al., The influence of socioeconomic status on cannabis use among French adolescents. *J Adolesc Health*, 2012; 50: 395–402.

47. The New York Times 2013-05-05. <https://www.nytimes.com/2013/05/05/us/dzhokhar-tsarnaevs-dark-side-carefully-masked.html>
48. Miller, NS. & Oberbarnsheidt, T. (2017). Marijuana and law. *Journal of Addiction Research & Therapy*, 2017; S11: 014.
49. The Atlantic 2013-04-23 <http://www.thewire.com/national/2013/04/dzhokhar-tsarnaev-dealing-drugs/64529/>
50. Report of the Indian Hemp Drugs Commission. Note of Dissent by Lala Nihal Chand. Citerad i Mills, James H (2003). *Cannabis Britannica* sid. 122–124.
51. Monshouwer, K. et al (2006). Cannabis use and mental health in secondary school children Findings from a Dutch survey. *The British Journal of Psychiatry*; 2: 148–153.
52. Norström T & Rossow I. Cannabis use and violence: Is there a link? *Scand J Public Health*. 2014; 42: 358–63.
53. Dugré, JR. et al (2017). Persistency of Cannabis Use Predicts Violence following Acute Psychiatric Discharge. *Frontiers in Psychiatry*, 2017: 8.
54. Socialstyrelsens statistikdatabas 2019-02-07 Tillgänglig: <http://www.socialstyrelsen.se/statistik/statistikdatabas/lakemedel>
55. Rice J & Cameron M. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. *Curr Neurol Neurosci Rep*. 2018; 19: 18–50.
56. Stockings et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. *Pain* 2018; 159: 1932–1954.
57. Wang, GS. et al. Impact of Marijuana Legalization in Colorado on Adolescent Emergency and Urgent Care Visits. *Journal of Adolescent Health*. 2018; 63: 239–241.
58. Chen Y-C, Klig JE. Cannabis-related emergencies in children and teens. *Curr Opin Pediatr* 2019; 31: 291–296.
59. Delling FN, Vittinghof E, Dewland TA, et al. Does cannabis legalisation change healthcare utilisation? *BMJ Open* 2019; 9: e027432.